Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Hell J Nucl Med. 2021 Sep-Dec;24(3):239-246. doi: 10.1967/s002449912407. Epub 2021 Dec 17.
Positron emission tomography/computed tomography (PET/CT) represents a reliable promising tool in treatment response evaluation of new therapies beyond Imatinib in gastrointestinal stromal tumors (GIST). This narrative review aims to discuss the literature about the role of fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT in evaluating response in new tyrosine kinase inhibitors (TKI) and radiotherapy (RT) in GIST patients. A comprehensive literature search was performed to retrieve original studies published on PubMed, Scopus and Google Scholar databases. Eighteen studies including 382 patients with GIST were selected. Main findings of included studies are presented. Fluorine-18-FDG PET/CT may enhance performance in GIST management providing significant information in evaluation of treatment response and representing a strong predictor of clinical outcome.
正电子发射断层扫描/计算机断层扫描（PET/CT）在胃肠道间质瘤（GIST）中，作为一种超越伊马替尼的新疗法的治疗反应评估的可靠工具，具有广阔的应用前景。本综述旨在讨论氟-18-氟代脱氧葡萄糖（F-FDG）PET/CT 在评估新型酪氨酸激酶抑制剂（TKI）和放疗（RT）在 GIST 患者中的疗效中的作用。在 PubMed、Scopus 和 Google Scholar 数据库中进行了全面的文献检索，以检索发表的原始研究。共选择了 18 项研究，共纳入 382 例 GIST 患者。介绍了纳入研究的主要发现。氟-18-FDG PET/CT 可能会提高 GIST 管理的效能，为治疗反应的评估提供重要信息，并作为临床结果的有力预测因素。
